Publications by authors named "Jeremy Hoog"

32Publications

Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER breast cancer.

FASEB J 2019 02 30;33(2):1644-1657. Epub 2018 Aug 30.

Department of Molecular and Systems Biology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, USA.

View Article

Download full-text PDF

Source
https://www.fasebj.org/doi/10.1096/fj.201801241R
Publisher Site
http://dx.doi.org/10.1096/fj.201801241RDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6338642PMC
February 2019

Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).

J Clin Oncol 2017 Apr 3;35(10):1061-1069. Epub 2017 Jan 3.

Matthew J. Ellis and Chad J. Creighton, Baylor College of Medicine; Gildy Babiera and Kelly Hunt, MD Anderson Cancer Center, Houston; Gary Unzeitig, Doctor's Hospital of Laredo, Laredo; Marilyn Leitch, University of Texas Southwestern Campus, Dallas, TX; Vera J. Suman, Mayo Clinic, Rochester MN; Jeremy Hoog, Rodrigo Goncalves, Souzan Sanati, Katherine DeSchryver, Erika Crouch, Amy Brink, Mark Watson, Jingqin Luo, Yu Tao, Cynthia X. Ma, and D. Craig Allred, Washington University School of Medicine, St Louis; Timothy Pluard, St Lukes Hospital, Kansas City, MO; Michael Barnes, Roche Diagnostics, Mountain View; Laura Esserman, University of California San Francisco, San Francisco, CA; Mitchell Dowsett, Royal Marsden Hospital, London, UK; G. Thomas Budd, Cleveland Clinic; Paula Silverman, Case Western Reserve University, Cleveland OH; Eric Winer, Dana-Farber Cancer Institute, Boston MA; Lisa Carey, University of North Carolina, Chapel Hill; David Ota, Duke University, Durham, NC; Pat Whitworth, Nashville Breast Center, Nashville, TN; J. Michael Guenther, St Elizabeth Medical Center, Edgewood, KY; Zoneddy Dayao, University of New Mexico, Albuquerque, NM; and John A. Olson Jr, University of Maryland School of Medicine and Greenebaum Cancer Center, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.4406DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455353PMC
April 2017

Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer.

Oncotarget 2016 Aug;7(35):56864-56875

Section of Medical Oncology, Division of Oncology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO, USA.

View Article

Download full-text PDF

Source
http://www.oncotarget.com/fulltext/10870
Publisher Site
http://dx.doi.org/10.18632/oncotarget.10870DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302958PMC
August 2016

Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.

J Clin Invest 2012 Apr 26;122(4):1541-52. Epub 2012 Mar 26.

Section of Breast Oncology, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri 63110-1093, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/JCI58765DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3314455PMC
April 2012